Thera-SAbDab

IFABOTUZUMAB

>   Structural Summary
TherapeuticIfabotuzumab
TargetEPHA3
Heavy ChainQVQLVQSGAEVKKPGASVKVSCKASGYTFTGYWMNWVRQAPGQGLEWMGDIYPGSGNTNYDEKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARGGYYEDFDSWGQGTTVTVSS
Light ChainDIQMTQSPSFLSASVGDRVTITCRASQGIISYLAWYQQKPEKAPKRLIYAASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCGQYANYPYTFGQGTKLEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (October '21)Phase-II
Estimated Status (October '21)Active
Recorded Developmental TechnologyPOTELLIGENT Technology;Humaneering Technology
INN Year Proposed2015
INN Year Recommended2017
Companies InvolvedLudwig Institute for Cancer Research, Humanigen, Olivia Newton-John Cancer Research Institute
Conditions Approvedna
Conditions ActiveAcute myeloid leukaemia, Myelodysplastic syndromes, Myelofibrosis, Glioblastoma
Conditions Discontinuedna
NotesIfabotuzumab is the new name for Fibatuzumab (PL115)

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy